The primary objective was to find the pharmacological targets of doxorubicin and their mechanisms of action, with a dual focus on their therapeutic relevance in skin cancer treatment and their potential involvement in resistance to doxorubicin in cancer cells. The targets of skin cancer and potential targets of doxorubicin were searched from multiple databases. Common targets were chosen using the GeneVenn tool and then imported into the STRING database to construct a protein–protein interaction network. Topological factors were evaluated with Cytoscape to identify core targets. FunRich was used to identify the signaling pathways, molecular functions, cellular components, and biological processes involving the top targets. Molecular docking was conducted using the Molecular Operating Environment software. The top five target genes identified as therapeutic targets of doxorubicin for treatment of skin cancer are poly(ADP-ribose) polymerase, epidermal growth factor receptors, heat shock protein 90 alpha family class A member 1, Harvey rat sarcoma viral oncogene homolog, and mammalian target of rapamycin. In addition, doxorubicin-induced resistance mechanisms were also predicted. Further research on innovative methods of delivering doxorubicin to maximize its effectiveness in treating skin cancer and to prevent the development of resistance to the drug is necessary.
Get full access to this article
View all access options for this article.
References
1.
IjazS, AkhtarN, KhanMS, et al.Plant derived anticancer agents: A green approach towards skin cancers. Biomed Pharmacother, 2018; 103:1643–1651; doi: 10.1016/j.biopha.2018.04.113
2.
CiążyńskaM, Kamińska-WinciorekG, LangeD, et al.The incidence and clinical analysis of non-melanoma skin cancer. Sci Rep, 2021; 11(1):4337; doi: 10.1038/s41598-021-83502-8
3.
KarhanaS, BhatM, NinaweA, et al.Advances in microscopy and their applications in biomedical research. In: Biomedical Imaging Instrumentation. Elsevier; 2022; pp. 185–212; doi: 10.1016/B978-0-323-85650-8.00008-5
4.
GargA, KhanI, KhanMA, et al.Current progress in targeting telomere and telomerase enzymes for the treatment of cancer. Cctr, 2024; 20(1):26–39; doi: 10.2174/1573394719666230331113753
5.
WeissR, SarosyG, Clagett-CarrK, et al.Anthracycline analogs: The past, present, and future. Cancer Chemother Pharmacol, 1986; 18(3):185–197; doi: 10.1007/BF00273384
6.
D’AngeloNA, NoronhaMA, CâmaraMCC, et al.Doxorubicin nanoformulations on therapy against cancer: An overview from the last 10 years. Biomater Adv, 2022; 133:112623; doi: 10.1016/j.msec.2021.112623
7.
SohailM, SunZ, LiY, et al.Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy. Expert Rev Anticancer Ther, 2021; 21(12):1385–1398; doi: 10.1080/14737140.2021.1991316
8.
AnsariL, ShiehzadehF, TaherzadehZ, et al.The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: A systematic review of clinical trials. Cancer Gene Ther, 2017; 24(5):189–193; doi: 10.1038/cgt.2017.9
9.
O’BrienMER, WiglerN, InbarM, et al.Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Annals of Oncology, 2004; 15(3):440–449; doi: 10.1093/annonc/mdh097
10.
CagelM, GrotzE, BernabeuE, et al.Doxorubicin: Nanotechnological overviews from bench to bedside. Drug Discov Today, 2017; 22(2):270–281; doi: 10.1016/j.drudis.2016.11.005
11.
GouM, ShiH, GuoG, et al.Improving anticancer activity and reducing systemic toxicity of doxorubicin by self-assembled polymeric micelles. Nanotechnology, 2011; 22(9):e095102; doi: 10.1088/0957-4484/22/9/095102
12.
SheibaniM, AziziY, ShayanM, et al.Doxorubicin-induced cardiotoxicity: An overview on pre-clinical therapeutic approaches. Cardiovasc Toxicol, 2022; 22(4):292–310; doi: 10.1007/s12012-022-09721-1
13.
Al-MalkyHS, Al HarthiSE, OsmanA-MM. Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance. J Oncol Pharm Pract, 2020; 26(2):434–444; doi: 10.1177/1078155219877931
14.
SritharanS, SivalingamN. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci, 2021; 278:119527; doi: 10.1016/j.lfs.2021.119527
15.
XuM, LiS. Nano-drug delivery system targeting tumor microenvironment: A prospective strategy for melanoma treatment. Cancer Lett, 2023; 574:216397; doi: 10.1016/j.canlet.2023.216397
16.
DulfPL, MocanM, CoadăCA, et al.Doxorubicin-induced acute cardiotoxicity is associated with increased oxidative stress, autophagy, and inflammation in a murine model. Naunyn Schmiedebergs Arch Pharmacol, 2023; 396(6):1105–1115; doi: 10.1007/s00210-023-02382-z
17.
GuoB, TamA, SantiSA, et al.Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells. BMC Cancer, 2016; 16(1):762; doi: 10.1186/s12885-016-2790-3
18.
ChristowitzC, DavisT, IsaacsA, et al.Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model. BMC Cancer, 2019; 19(1):757; doi: 10.1186/s12885-019-5939-z
19.
SinghS. Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells. Int J Nanomedicine, 2018; 13(T-NANO 2014 Abstracts):11–13; doi: 10.2147/IJN.S124701
20.
TupalA, SabzichiM, RamezaniF, et al.Dermal delivery of doxorubicin-loaded solid lipid nanoparticles for the treatment of skin cancer. J Microencapsul, 2016; 33(4):372–380; doi: 10.1080/02652048.2016.1200150
21.
KanwalU, RazaA, AbbasM, et al.Nanomedicine-based doxorubicin delivery for skin cancer with theranostic potential. In: Advanced Drug Delivery Systems in the Management of Cancer. Elsevier; 2021; pp. 207–215; doi: 10.1016/B978-0-323-85503-7.00041-9
22.
KhanTZ, NewajSM, RahmanA, et al.NIR-light-triggered delivery of doxorubicin-loaded PLGA nanoparticles for synergistic cancer therapy on DMBA/TPA induced tumor-bearing Mice. Mater Adv, 2023; 4(21):5175–5183; doi: 10.1039/D3MA00375B
23.
AnL, ZhangP, ShenW, et al.A sulfur dioxide polymer prodrug showing combined effect with doxorubicin in combating subcutaneous and metastatic melanoma. Bioact Mater, 2021; 6(5):1365–1374; doi: 10.1016/j.bioactmat.2020.10.027
24.
ChenZ, HuangQ, SongY, et al.Cubosomes-assisted transdermal delivery of doxorubicin and indocyanine green for chemo-photothermal combination therapy of melanoma. Biomed Pharmacother, 2023; 166:115316; doi: 10.1016/j.biopha.2023.115316
25.
LeeJ, WangY, XueC, et al.pH-Responsive doxorubicin delivery using shear-thinning biomaterials for localized melanoma treatment. Nanoscale, 2022; 14(2):350–360; doi: 10.1039/D1NR05738C
26.
RadevaL, ZaharievaMM, SpassovaI, et al.Biopolymeric nanogel as a drug delivery system for doxorubicin—improved drug stability and enhanced antineoplastic activity in skin cancer cells. Pharmaceuticals, 2024; 17(2):186; doi: 10.3390/ph17020186
27.
ShurfaMK, GirigoswamiA, Sakthi DeviR, et al.Combinatorial effect of doxorubicin entrapped in alginate-chitosan hybrid polymer and cerium oxide nanocomposites on skin cancer management in Mice. J Pharm Sci, 2023; 112(11):2891–2900; doi: 10.1016/j.xphs.2023.08.014
28.
ZhaiZ, TaoX, AlamiMM, et al.Network pharmacology and molecular docking combined to analyze the molecular and pharmacological mechanism of Pinellia ternata in the treatment of hypertension. Curr Issues Mol Biol, 2021; 43(1):65–78; doi: 10.3390/cimb43010006
29.
TaoY, HuangX-F, WangJ, et al.Exploring molecular mechanism of Huangqi in treating heart failure using network pharmacology. Evid Based Complement Alternat Med, 2020; 2020:6473745; doi: 10.1155/2020/6473745
30.
ShakerB, AhmadS, LeeJ, et al.In silico methods and tools for drug discovery. Comput Biol Med, 2021; 137:104851; doi: 10.1016/j.compbiomed.2021.104851
31.
MaoY, PengX, XueP, et al.Network pharmacology study on the pharmacological mechanism of cinobufotalin injection against lung cancer. Evid Based Complement Alternat Med, 2020; 2020:1246742; doi: 10.1155/2020/1246742
32.
PiñeroJ, BravoÀ, Queralt-RosinachN, et al.DisGeNET: A comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res, 2017; 45(D1):D833–D839; doi: 10.1093/nar/gkw943
33.
KillcoyneS, CarterGW, SmithJ, et al.Cytoscape: A community-based framework for network modeling. Methods Mol Biol, 2009; 563:219–239; doi: 10.1007/978-1-60761-175-2_12
34.
Al-HazmiGAA, Abou-MelhaKS, El-MetwalyNM, et al.Green synthesis for 3-(2-benzoylhydrazono)-N-(pyridin-2-yl)butanamide complexes: Spectral, analytical, modelling, MOE docking and biological studies. J Inorg Organomet Polym, 2020; 30(5):1519–1536; doi: 10.1007/s10904-019-01326-6
35.
OhKK, AdnanM, ChoDH. Network pharmacology approach to decipher signaling pathways associated with target proteins of NSAIDs against COVID-19. Sci Rep, 2021; 11(1):9606; doi: 10.1038/s41598-021-88313-5
36.
BegMR, LaeeqA, SathayeS. Pharmacological target and the biological mechanism of gallic acid for anticataract effect: A network analysis. Phytomedicine Plus, 2022; 2(2):100258; doi: 10.1016/j.phyplu.2022.100258
37.
ChakrabortyR, GuptaH, RahmanR, et al.In silico analysis of nsSNPs in ABCB1 gene affecting breast cancer associated protein P-glycoprotein (P-gp). Comput Biol Chem, 2018; 77:430–441; doi: 10.1016/j.compbiolchem.2018.08.004
38.
LiR, MaX, SongY, et al.Anti‐colorectal cancer targets of resveratrol and biological molecular mechanism: Analyses of network pharmacology, human and experimental data. J Cell Biochem, 2019; 120(7):11265–11273; doi: 10.1002/jcb.28404
39.
WuY-S, ShiL, LiuX-G, et al.Chemical profiling of Callicarpa nudiflora and its effective compounds identification by compound-target network analysis. J Pharm Biomed Anal, 2020; 182:113110; doi: 10.1016/j.jpba.2020.113110
40.
PathanM, KeerthikumarS, AngC, et al.FunRich: An open access standalone functional enrichment and interaction network analysis tool. Proteomics, 2015; 15(15):2597–2601; doi: 10.1002/pmic.201400515
41.
GargA, SinghA, KumarA. Selective estrogen receptor modulators against Gram-positive and Gram-negative bacteria: An experimental study. Future Microbiol, 2021; 16(13):987–1001; doi: 10.2217/fmb-2020-0310
42.
KarhanaS, DabralS, GargA, et al.Network pharmacology and molecular docking analysis on potential molecular targets and mechanism of action of BRAF inhibitors for application in wound healing. J Cell Biochem, 2023; 124(7):1023–1039; doi: 10.1002/jcb.30430
43.
IndarteM, MaduraJD, SurrattCK. Dopamine transporter comparative molecular modeling and binding site prediction using the LeuTAa leucine transporter as a template. Proteins: Structure, Function, and Bioinformatics, 2008; 70(3):1033–1046; doi: 10.1002/prot.21598
44.
Giglia-MariG, SarasinA. TP53 mutations in human skin cancers. Hum Mutat, 2003; 21(3):217–228; doi: 10.1002/humu.10179
45.
SahaT, KarRK, SaG. Structural and sequential context of p53: A review of experimental and theoretical evidence. Prog Biophys Mol Biol, 2015; 117(2–3):250–263; doi: 10.1016/j.pbiomolbio.2014.12.002
46.
RaimundoL, RamosH, LoureiroJB, et al.BRCA1/P53: Two strengths in cancer chemoprevention. Biochim Biophys Acta Rev Cancer, 2020; 1873(1):188339; doi: 10.1016/j.bbcan.2020.188339
47.
LoureiroJB, AbrantesM, OliveiraPA, et al.P53 in skin cancer: From a master player to a privileged target for prevention and therapy. Biochim Biophys Acta Rev Cancer, 2020; 1874(2):188438; doi: 10.1016/j.bbcan.2020.188438
48.
WangS, El-DeiryWS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene, 2003; 22(53):8628–8633; doi: 10.1038/sj.onc.1207232
49.
MacFarlaneM. TRAIL-induced signalling and apoptosis. Toxicol Lett, 2003; 139(2–3):89–97; doi: 10.1016/S0378-4274(02)00422-8
WangF, MosemanA, DoucetteM, et al.Abstract 288: PDGFR alpha and PDGFR beta differentially regulate cell proliferation and migration/invasion in medulloblastoma cells. Cancer Res, 2010; 70(8_Supplement):288–288; doi: 10.1158/1538-7445.AM10-288
52.
XingS, WangC, TangH, et al.Down‐regulation of PDGFRβ suppresses invasion and migration in osteosarcoma cells by influencing epithelial–mesenchymal transition. FEBS Open Bio, 2020; 10(9):1748–1757; doi: 10.1002/2211-5463.12915
53.
CasalouC, FaustinoA, BarralDC. Arf proteins in cancer cell migration. Small GTPases, 2016; 7(4):270–282; doi: 10.1080/21541248.2016.1228792
SabeH. Requirement for Arf6 in cell adhesion, migration, and cancer cell invasion. J Biochem, 2003; 134(4):485–489; doi: 10.1093/jb/mvg181
56.
FoukasLC, BerenjenoIM, GrayA, et al.Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A, 2010; 107(25):11381–11386; doi: 10.1073/pnas.0906461107
57.
YuJSL, CuiW. Proliferation, survival and metabolism: The role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development, 2016; 143(17):3050–3060; doi: 10.1242/dev.137075
58.
LiR, PengC, ZhangX, et al.Roles of Arf6 in cancer cell invasion, metastasis and proliferation. Life Sci, 2017; 182:80–84; doi: 10.1016/j.lfs.2017.06.008
59.
ParkJ, JangJ-H, OhS, et al.LPA-induced migration of ovarian cancer cells requires activation of ERM proteins via LPA1 and LPA2. Cell Signal, 2018; 44:138–147; doi: 10.1016/j.cellsig.2018.01.007
60.
PuaTL, WangF, FishmanDA. Roles of LPA in ovarian cancer development and progression. Future Oncol, 2009; 5(10):1659–1673; doi: 10.2217/fon.09.120
61.
YenC-F, WangH-S, LeeC-L, et al.Roles of integrin-linked kinase in cell signaling and its perspectives as a therapeutic target. Gynecol Minim Invasive Ther, 2014; 3(3):67–72; doi: 10.1016/j.gmit.2014.06.002
62.
WongRPC, NgP, DedharS, et al.The role of integrin-linked kinase in melanoma cell migration, invasion, and tumor growth. Mol Cancer Ther, 2007; 6(6):1692–1700; doi: 10.1158/1535-7163.MCT-07-0134
63.
HuangW-C, NagahashiM, TerracinaK, et al.Emerging role of sphingosine-1-phosphate in inflammation, cancer, and lymphangiogenesis. Biomolecules, 2013; 3(3):408–434; doi: 10.3390/biom3030408
64.
De VosM, SchreiberV, DantzerF. The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art. Biochem Pharmacol, 2012; 84(2):137–146; doi: 10.1016/j.bcp.2012.03.018
65.
CurtinNJ, SzaboC. Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond. Mol Aspects Med, 2013; 34(6):1217–1256; doi: 10.1016/j.mam.2013.01.006
66.
ChanWY, BrownLJ, ReidL, et al.PARP inhibitors in melanoma—An expanding therapeutic option? Cancers (Basel), 2021; 13(18):4520; doi: 10.3390/cancers13184520
67.
WeaverAN, YangES. Beyond DNA repair: Additional functions of PARP-1 in cancer. Front Oncol, 2013; 3:290; doi: 10.3389/fonc.2013.00290
68.
SatoK. Cellular functions regulated by phosphorylation of EGFR on Tyr845. Int J Mol Sci, 2013; 14(6):10761–10790; doi: 10.3390/ijms140610761
69.
JosephSR, Endo-MunozL, GaffneyDC, et al.Dysregulation of epidermal growth factor receptor in actinic keratosis and squamous cell carcinoma. Curr Probl Dermatol, 2015; 46:20–27; doi: 10.1159/000367959
70.
SuomelaS, ElomaaO, SkoogT, et al.CCHCR1 is up-regulated in skin cancer and associated with EGFR expression. PLoS One, 2009; 4(6):e6030; doi: 10.1371/journal.pone.0006030
71.
PetrilliR, EloyJO, SaggioroFP, et al.Skin cancer treatment effectiveness is improved by iontophoresis of EGFR-targeted liposomes containing 5-FU compared with subcutaneous injection. J Control Release, 2018; 283:151–162; doi: 10.1016/j.jconrel.2018.05.038
72.
BirboB, MaduEE, MaduCO, et al.Role of HSP90 in Cancer. Int J Mol Sci, 2021; 22(19):10317; doi: 10.3390/ijms221910317
73.
XiaoX, WangW, LiY, et al.HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma. J Exp Clin Cancer Res, 2018; 37(1):201; doi: 10.1186/s13046-018-0880-6
74.
DrostenM, DhawahirA, SumEYM, et al.Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. Embo J, 2010; 29(6):1091–1104; doi: 10.1038/emboj.2010.7
75.
van der SchroeffJG, EversLM, BosJL, et al.Ras oncogene mutations in basal cell carcinomas and squamous cell carcinomas of human skin. J Invest Dermatol, 1990; 94(4):423–425.
76.
FingarDC, BlenisJ. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene, 2004; 23(18):3151–3171; doi: 10.1038/sj.onc.1207542
77.
PópuloH, LopesJM, SoaresP. The mTOR signalling pathway in human cancer. Int J Mol Sci, 2012; 13(2):1886–1918; doi: 10.3390/ijms13021886
78.
NoorF, Tahir Ul QamarM, AshfaqUA, et al.Network pharmacology approach for medicinal plants: Review and assessment. Pharmaceuticals (Basel), 2022; 15(5):572; doi: 10.3390/ph15050572
79.
ZhangQ, LiX, LiJ, et al.Mechanism of anti-inflammatory and antibacterial effects of QingXiaoWuWei decoction based on network pharmacology, molecular docking and in vitro experiments. Front Pharmacol, 2021; 12:678685; doi: 10.3389/fphar.2021.678685
80.
GargA, KarhanaS, BanoA, et al.Network pharmacology and molecular docking study-based approach to explore mechanism of benzimidazole-based anthelmintics for the treatment of lung cancer. J Biomol Struct Dyn, 2024; 42(20):10739–10760; doi: 10.1080/07391102.2023.2258419
